Role of Early Versus Late Switch to Lapatinib-Capecitabine

You may be eligible if

• Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice);
• Older than 18 years old;
• Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;
• Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;
• Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, in the community setting;
• Signed consent to participate and release information for this study.